Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
- Tuesday, January 31, 2023, 7:12
- PR Newswire
- Add a comment
FCS is a rare and debilitating genetic disease often leading to significant risk of acute, potentially fatal pancreatitis If approved, olezarsen would be the first approved treatment for FCS in the U.S. CARLSBAD, Calif., Jan. 31, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq:…
About the Author
admin has written 20650 stories on this site.